<DOC>
	<DOC>NCT00450775</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.</brief_summary>
	<brief_title>Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars</brief_title>
	<detailed_description />
	<criteria>Female or male patients at least 18 years of age Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc) Able and willing to provide informed consent and likely to complete all study visits All Fitzpatrick skin types will be evaluated Known contraindications to Dermatix or any of its components Age of scar is &gt; 4 months Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>